Re2O in Daegu: which skin it suits and which it doesn’t
Re2O starts from a different place than other boosters that “make collagen.” It places dermal matrix from human skin with the cells removed (hADM) directly in the dermis. So the line between skin it suits and skin it doesn’t is relatively clear. I have set out that line, how far human research goes, and how it differs from CellREDM in the same family.
The short answer
Re2O is a skin booster that injects into the dermis a dermal matrix (hADM) from donated human skin with the cells and DNA removed; skin where the dermis has thinned, with many fine lines and showing through, is a candidate. There is a 20-person · 20-week split-face double-blind randomised trial at Yonsei Severance Hospital (hyaluronic acid on the other side), but it is exploratory in scale, and no human trial has directly confirmed that it “suits thin skin especially well.” It doesn’t suit faces where weight and volume are the problem, such as hollow cheeks · sagging. Miso Clinic in Daegu (4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, +82-53-428-2700) tells you the origin of the material first, starts with three sessions a month apart as the baseline, and decides on more by progress (clinical judgement).
What does a Re2O treatment put in?
Re2O’s material is hADM (human acellular dermal matrix). It is a matrix made by stripping the epidermis from donated human skin and removing the cells and DNA, leaving only structural components such as collagen · elastin. This is made into a freeze-dried powder that is mixed and injected. It is a product of L&C Bio · Humedix, released in November 2024.
Where most boosters give the skin a signal to “make,” hADM is on the side of adding material to that layer. The evidence within the same family is in hADM boosters: how far the evidence goes.
Which skin is a Re2O candidate?
| Situation | Why it is a candidate |
|---|---|
| Skin is thin and shows through | It targets the dermis itself |
| Many small fine lines | Closer to surface sparseness than to one deep groove |
| Thin areas such as around the eyes | An option where volume products are hard to use |
| Rough texture, uneven light reflection | A matter of surface pattern, not weight |
To add honestly — I found no data confirming directly in a human trial that it is “especially good for thin skin.” The table above is a criterion drawn from the layer the product targets and from clinical judgement (clinical judgement).
Which faces does Re2O not suit?
The cheeks have hollowed, the lower face has grown heavy, the jawline has blurred — if concerns like these are central, Re2O doesn’t suit. The amount of material added to the dermis can hardly change the weight of the face.
Looking at layer thickness shows why. In 3D measurement of 30 cadavers, skin was 2.1 ± 0.4 mm and the superficial fat beneath it 5.2 ± 1.9 mm (Lee 2021). The face’s volume and individual variation are far greater in the fat layer than in the dermis. A design that tries to solve a fat-layer problem with a dermal product is a design aimed at the wrong layer.
There is also a distinction you can try at home. If the spot that bothers you fades when you lie down, or the line smooths when you lift the cheek slightly, it is closer to sagging. This is not a validated diagnostic method but an observation Miso Clinic uses in practice (clinical judgement). If it is sagging, look first at booster or lifting.
How far does human research go?
Re2O has a split-face double-blind randomised trial from Yonsei University Severance Hospital (NCT07155278, Int J Mol Sci 2026). Twenty people had Re2O on one side and hyaluronic acid on the other, compared over 20 weeks. Comparing left and right in the same person is a design that cancels out variables such as age · skin thickness.
- Strengths — split-face · double-blind · randomised design, active control (hyaluronic acid)
- Limits — exploratory scale of 20 people, observation up to 20 weeks
- Not found — dose per injection, safety when layered with other boosters, trials of a reversing agent
Long experience with hADM sheets in surgery only speaks to the nature of the material (a matrix with low rejection risk); it does not guarantee results or duration for an injectable cosmetic treatment. So Miso Clinic doesn’t use phrases like “lasts so many months.” The overall evidence is in Re2O evidence.
How does it differ from CellREDM?
| Item | Re2O | CellREDM |
|---|---|---|
| Manufacturer · distributor | L&C Bio · Humedix | Made by Hans Biomed · Korean rights Hugel |
| Released | November 2024 | September 2025 |
| Published features | Split-face randomised trial (20 people) | Fine particles about 75 μm (manufacturer’s figure) |
| Published human trial of the product itself | Yes (exploratory) | Not found |
There is no trial comparing the two products directly, so I don’t say which is better. The smaller-particle one tends to be easier to divide across thin, sensitive areas, so Miso Clinic chooses or divides by area and goal (clinical judgement). See also CellREDM and Re2O in Daegu: what differs.
Can it be reversed, and what does “human tissue” mean?
There is no reversing injection. hADM is not hyaluronic acid and does not dissolve with hyaluronidase. As a material the body breaks down it is not a permanent structure, but there is no means of removing it right after injection, so we start on the low side and add later (clinical judgement).
Re2O is handled not as a medical device but as human tissue. Under the Act on the Safety and Management of Human Tissue, tissue bank licensing and import rules apply, and a record is kept of donation → processing → testing → storage → distribution. In July 2026 the MFDS gave advance notice of an amendment to the enforcement rules; as of September it had not been promulgated.
If the material coming from people bothers you, we won’t push it. For the same goal there are other families such as Gouri or Rejuran.
In what order does Miso Clinic decide?
- We first divide the concern into texture · thickness · volume. Before this sorting we don’t mention product names.
- If volume is the main concern, we tell you the direction is different.
- We look directly at skin thickness by area. In thin areas we reduce the amount and increase the points.
- We check materials already placed in the same area, and if they overlap we divide by area or timing.
- We start with three sessions a month apart as the baseline, and decide on more by progress, not by the calendar.
The order above is all Miso Clinic’s clinical criteria (clinical judgement). Sessions are covered in the Re2O sessions guide.
Which skin suits Re2O in Daegu: frequently asked questions
What skin does Re2O suit?
Skin where the dermis has thinned, with many fine lines and showing through, is a candidate. But no human trial has directly confirmed it suits thin skin especially well.
Can Re2O fix hollow cheeks?
It doesn’t suit. What governs facial volume is the fat layer below the dermis rather than the dermis, and in cadaver measurement the superficial fat was 5.2 ± 1.9 mm with large individual variation.
Is there research on Re2O?
There is a 20-person · 20-week split-face double-blind randomised trial at Yonsei Severance Hospital (hyaluronic acid on the other side, NCT07155278). Its exploratory scale must be kept in view.
How do Re2O and CellREDM differ?
Both are in the hADM family. CellREDM has small particles of about 75 μm, and we found no published human trial of the product itself. With no head-to-head trial, we don’t rank them.
Can Re2O be dissolved?
It doesn’t dissolve with hyaluronidase. As a degradable material it doesn’t stay permanently, but there is no reversing injection, so Miso Clinic starts small, watches progress and adds.
Where can I get a Re2O consultation in Daegu?
Miso Clinic in Daegu is at 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, in front of Exit 1 of Kyungpook National University Hospital Station. +82-53-428-2700; weekdays 11:00–19:00 · Saturday 10:00–16:00 (no lunch break); closed Sundays · public holidays.
Clinical columns to read next
- Re2O in Daegu: needle vs cannula, what differs?
- Skin boosters in Daegu: where to start
- Re2O in Daegu: which skin does it suit?
- Re2O (hADM) in Daegu — what goes in and what has been observed
- CellREDM · Re2O and Rejuran — they put in different things
- CellREDM and Re2O in Daegu: what differs?
- Skin that suits Rejuran
- Gouri vs Re2O compared
Product reference
Product references: Re2O · CellREDM · Re2O treatment guide
Clinic
This column was written and reviewed by Lee Chi-Hak, MD, medical director of Miso Clinic in Daegu. The treatment criteria and injection design are written exactly as we actually use them.
| Medical Director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu (Exit 1, Kyungpook National University Hospital Station) · tower parking in the building |
| Phone | 053-428-2700 |
| KakaoTalk consultation | Miso Clinic Daegu channel |
| KakaoTalk channel | Add the channel |
| Opening hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Clinical column | See all columns |
| Reference library | All booster and lifting device references |
References
- Re2O split-face trial — Yonsei University Severance Hospital, split-face double-blind randomised trial (NCT07155278), International Journal of Molecular Sciences 2026. 20 people · 20 weeks · Re2O on one side, hyaluronic acid on the other. Exploratory in scale.
- Re2O product information — made by L&C Bio · Humedix, released November 2024. Dermal matrix (hADM) from donated human skin with cells · DNA removed, made into freeze-dried powder, mixed and injected. Trial registration NCT07155278 — three intradermal injections a month apart. Dose per injection not found in the paper · registry · manufacturer materials. (cited in /column/hadm-vs-pn/ · /column/daegu-rituo-skin-fit/)
- CellREDM product information — made by Hans Biomed (Korean rights Hugel). hADM fine particles about 75 μm (manufacturer’s figure). We found no published human trial of CellREDM itself.
- Human tissue rules — Act on the Safety and Management of Human Tissue (tissue bank licence Art. 13 · import Art. 17). MFDS Notice No. 2026-340 of 16 July 2026 gave advance notice of an amendment to the enforcement rules; not promulgated as of September 2026.
- Individual variation in facial layer thickness — Lee KW et al., Clinical Anatomy 2021;34(7):1050–1058, PMID 33583088. 3D measurement of 30 fixed cadavers; skin 2.1 ± 0.4 mm, superficial fat 5.2 ± 1.9 mm.
- Korean medical advertising law — Medical Service Act Article 56(2), which prohibits testimonial advertising, comparison with other medical institutions and superlative claims.
- Miso Clinic clinical guidelines — criteria for indications, design by area, pre-treatment explanation and consent. The source of sentences marked “clinical judgement” in this column.
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.